Amoy Diagnostics Co., Ltd. (300685.SZ)
CNY 20.9
(-0.9%)
CNY 20.9
(-0.9%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.93 Billion CNY | 17.2% |
| 2022 | 1.65 Billion CNY | 8.62% |
| 2021 | 1.51 Billion CNY | 17.56% |
| 2020 | 1.29 Billion CNY | 23.51% |
| 2019 | 1.04 Billion CNY | 27.85% |
| 2018 | 818.74 Million CNY | 17.83% |
| 2017 | 694.84 Million CNY | 96.67% |
| 2016 | 353.3 Million CNY | 16.81% |
| 2015 | 302.45 Million CNY | 71.42% |
| 2014 | 176.44 Million CNY | 59.89% |
| 2013 | 110.35 Million CNY | 65.07% |
| 2012 | 66.85 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 2.03 Billion CNY | 2.38% |
| 2024 Q2 | 1.98 Billion CNY | 0.7% |
| 2024 Q1 | 1.97 Billion CNY | 2.04% |
| 2023 Q3 | 1.76 Billion CNY | 3.3% |
| 2023 Q4 | 1.93 Billion CNY | 9.44% |
| 2023 FY | 1.93 Billion CNY | 17.2% |
| 2023 Q1 | 1.67 Billion CNY | 1.24% |
| 2023 Q2 | 1.71 Billion CNY | 2.4% |
| 2022 Q4 | 1.65 Billion CNY | 1.2% |
| 2022 Q1 | 1.53 Billion CNY | 1.0% |
| 2022 Q2 | 1.54 Billion CNY | 0.56% |
| 2022 FY | 1.65 Billion CNY | 8.62% |
| 2022 Q3 | 1.63 Billion CNY | 5.68% |
| 2021 Q3 | 1.42 Billion CNY | 5.12% |
| 2021 FY | 1.51 Billion CNY | 17.56% |
| 2021 Q1 | 1.34 Billion CNY | 4.13% |
| 2021 Q2 | 1.35 Billion CNY | 0.88% |
| 2021 Q4 | 1.51 Billion CNY | 6.45% |
| 2020 Q3 | 1.22 Billion CNY | 2.55% |
| 2020 FY | 1.29 Billion CNY | 23.51% |
| 2020 Q2 | 1.19 Billion CNY | 7.12% |
| 2020 Q1 | 1.11 Billion CNY | 6.71% |
| 2020 Q4 | 1.29 Billion CNY | 5.36% |
| 2019 Q2 | 950.22 Million CNY | 13.51% |
| 2019 Q3 | 1 Billion CNY | 5.88% |
| 2019 Q1 | 837.09 Million CNY | 2.24% |
| 2019 Q4 | 1.04 Billion CNY | 4.04% |
| 2019 FY | 1.04 Billion CNY | 27.85% |
| 2018 Q1 | 716.28 Million CNY | 3.09% |
| 2018 FY | 818.74 Million CNY | 17.83% |
| 2018 Q4 | 818.74 Million CNY | -0.11% |
| 2018 Q2 | 759.72 Million CNY | 6.06% |
| 2018 Q3 | 819.61 Million CNY | 7.88% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q3 | 679.73 Million CNY | 69.47% |
| 2017 Q4 | 694.84 Million CNY | 2.22% |
| 2017 FY | 694.84 Million CNY | 96.67% |
| 2017 Q2 | 401.1 Million CNY | 0.0% |
| 2016 FY | 353.3 Million CNY | 16.81% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q4 | 353.3 Million CNY | 0.0% |
| 2015 Q4 | 302.45 Million CNY | 0.0% |
| 2015 FY | 302.45 Million CNY | 71.42% |
| 2015 Q2 | 277.96 Million CNY | 0.0% |
| 2015 Q1 | 277.96 Million CNY | 0.0% |
| 2014 FY | 176.44 Million CNY | 59.89% |
| 2013 FY | 110.35 Million CNY | 65.07% |
| 2012 FY | 66.85 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 17.93 Billion CNY | 89.214% |
| Hangzhou Tigermed Consulting Co., Ltd. | 29.69 Billion CNY | 93.485% |
| Dirui Industrial Co.,Ltd. | 3.32 Billion CNY | 41.734% |
| Beijing Strong Biotechnologies, Inc. | 5.17 Billion CNY | 62.616% |
| Medicalsystem Biotechnology Co., Ltd. | 3.48 Billion CNY | 44.546% |
| Maccura Biotechnology Co.Ltd | 8.11 Billion CNY | 76.169% |
| Guangzhou Wondfo Biotech Co.,Ltd | 5.77 Billion CNY | 66.477% |
| Guangdong Hybribio Biotech Co.,Ltd. | 5.72 Billion CNY | 66.208% |
| BGI Genomics Co., Ltd. | 13.61 Billion CNY | 85.787% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 2.98 Billion CNY | 35.22% |